BioSpace News Archive

First clinical program in the world designed to assess the use of favipiravir for COVID-19 as prophylaxis for outbreak control; antiviral drug has shown early efficacy against COVID-19

AtriCure, Inc. announced it has commenced a proposed underwritten public offering in which it expects to issue and sell approximately $100 million of shares of its common stock pursuant to its existing automatic shelf registration statement.

OpGen, Inc., a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, to issued two letters to stockholders from new OpGen CEO Oliver Schacht and Chairman of the Board William Rhodes.

Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today reported financial results and recent corporate highlights for the first quarter ended March 31, 2020. “In the first quarter of 2020, the U.S. Food and Drug Administration (“FDA”) accepted our IV tramadol New Drug Application (“NDA”) submission for review and set a Prescription Drug User Fee Act (“PDUFA”

Highly Statistically Significant Improvements in NYHA Classification, Peak VO2, and LVOT Gradient Observed vs. Placebo

ContraFect Corporation, a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents, including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections, announced the publication of four abstracts in the 30th European Congress of Clinical Microbiology and Infectious Diseases abstract book.

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce that the Company has regained the commercialization and distribution rights in Europe for LYMPHOSEEK® (technetium Tc99m tilmanocept) injection from Norgine B.V. (“Norgine”). Navidea and Norgine have decided, by mutual agre

Fast Track Designation Granted for IPI-549 Plus Opdivo ® in Patients with Advanced Urothelial Cancer – – Infinity Voluntarily Pausing Enrollment on MARIO-275 to Evaluate the Risk/Benefit for Patients – – Completion of Enrollment for MARIO-275 and MARIO-3 Delayed with Outlook for Completion of Enrollment and Impact on Data Readouts to Be Updated by 2Q Earnings Webcast – – $20M Asset Backed Financing with BVF in January; Cash Runway into

Bristol Myers Squibb to buy out its ex-U.S. milestone and royalty obligations to bluebird bio for $200 million – - Bristol Myers Squibb assumes responsibility for vector manufacturing in ex-US territories – - bluebird to hold conference call and webcast today, May 11, 2020 at 8:00AM ET – CAMBRIDGE, Mass.--( BUSINESS WIRE )-- bluebird bio, Inc. (NASDAQ: BLUE) today announced that it has amended its existing co-promotion/co-development a

Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today that the U.S. Food and Drug Administration has approved its Investigational New Drug application for HST 001, the Company’s lead therapeutic candidate for the treatment of androgenic alopecia in men.